Drugs / MANELIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03464032 | Oct 2017 → May 2018 | melanoma, non-small cell lung carcinoma, renal cell carcinoma, urinary bladder cancer | Biocad | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MANELIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594528 ↗ |
| Known as | BCD-135 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03464032 ↗ |
| Modality | Monoclonal antibody | “Monoclonal anti-PD-L1 antibody” NCT03464032 ↗ |